

AstraZeneca PLC

2012 Annual General Meeting

26 April 2012

Welcome to our Annual General Meeting

AstraZeneca PLC

2012 Annual General Meeting

AstraZeneca PLC

2012 Annual General Meeting

Louis Schweitzer
Chairman



AstraZeneca PLC

2012 Annual General Meeting

Shriti Vadera
Non-Executive Director



AstraZeneca PLC

2012 Annual General Meeting

Rudy Markham
Non-Executive Director



AstraZeneca PLC

2012 Annual General Meeting

Michele Hooper
Non-Executive Director



AstraZeneca PLC

2012 Annual General Meeting

Simon Lowth
Chief Financial Officer



AstraZeneca PLC

2012 Annual General Meeting


David Brennan
Chief Executive Officer



AstraZeneca PLC

2012 Annual General Meeting

Bruce Burlington
Non-Executive Director



AstraZeneca PLC

2012 Annual General Meeting

Jean-Philippe Courtois
Non-Executive Director



AstraZeneca PLC

2012 Annual General Meeting

Nancy Rothwell
Non-Executive Director



AstraZeneca PLC

2012 Annual General Meeting

Marcus Wallenberg
Non-Executive Director



AstraZeneca PLC

2012 Annual General Meeting

John Varley

Non-Executive Director



AstraZeneca PLC

2012 Annual General Meeting

Louis Schweitzer
Chairman



AstraZeneca PLC

2012 Annual General Meeting

AstraZeneca PLC

2012 Annual General Meeting

Geneviève Berger



AstraZeneca PLC

2012 Annual General Meeting

Graham Chipchase



AstraZeneca PLC

2012 Annual General Meeting

Leif Johansson



AstraZeneca PLC

2012 Annual General Meeting

AstraZeneca PLC

2012 Annual General Meeting

David Brennan
Chief Executive Officer

Our vision

AstraZeneca is

Focused

Innovation-driven

Integrated

Global

Biopharma

Our values



Industry outlook

Growth Sector

- Increasing and ageing **populations**
- Expanding populations in **new markets**
- Significant **unmet medical need**
- Continued **scientific and technological advance**

Pressures on returns

- Decline in **R&D productivity**
- Established market **price pressure**
- **Patent expiries** and **genericisation**



Corporate strategic priorities

Making the most meaningful difference to patient health through great medicines

Pipeline

- Transform R&D organisation
- Improve quantity and quality of output
- More outward-looking and collaborative
- Drive productivity

Deliver the business

- Growth of current products
- Innovative channels to meet customer needs
- Drive growth in emerging markets
- Build stronger relationships with payers

Business shape

- Reshape and simplify business
- Restructure to improve competitiveness
- Invest to drive growth
- Manage change in the right way

People

- Acquiring and retaining talent
- Developing leaders
- Improving diversity
- Improving engagement

Manage for long-term shareholder value

Our values



Corporate strategic priorities

Pipeline

- Transform R&D organisation
- Improve quantity and quality of output
- More outward-looking and collaborative
- Drive productivity



Corporate strategic priorities

Deliver the business

- Growth of current products
- Innovative channels to meet customer needs
- Drive growth in emerging markets
- Build stronger relationships with payers



Corporate strategic priorities

Business shape

- Reshape and simplify business
- Restructure to improve competitiveness
- Invest to drive growth
- Manage change in the right way



Corporate strategic priorities

People

- Acquiring and retaining talent
- Developing leaders
- Improving diversity
- Improving engagement



Corporate strategic priorities

Values

- Committed to acting responsibly and to the sustainable development of our business
- Integrity and high ethical standards
- Global Policy on External Interactions
- Revised IFPMA Code of Conduct



AstraZeneca PLC

2012 Annual General Meeting

Headline results: 1Q 2012

	2012 \$m	2011 \$m	Actual growth	CER growth
Revenue	7,349	8,292	-11%	-11%
Core Operating Profit	2,997	3,678	-19%	-18%
Reported EPS	\$1.28	\$2.08	-38%	-39%
Core EPS	\$1.81	\$2.23	-19%	-19%



Key brand revenue summary: 1Q 2012

	2012 \$m	2011 \$m	CER growth
<i>Crestor</i>	1,500	1,478	+2%
<i>Seroquel IR</i>	754	1,006	-25%
<i>Seroquel XR</i>	384	339	+14%
<i>Symbicort</i>	723	752	-3%
<i>Arimidex</i>	144	233	-39%
<i>Nexium</i>	953	1,161	-18%



Regional revenue performance: 1Q 2012

	2012 \$m	2011 \$m	CER growth
Total Revenue	7,349	8,292	-11%
US	2,920	3,304	-12%
Western Europe	1,775	2,235	-19%
Established Rest of World	1,238	1,321	-9%
Emerging Rest of World	1,416	1,432	+1%



Headline results: 1Q 2012

	2012 \$m	2011 \$m	Actual growth	CER growth
Revenue	7,349	8,292	-11%	-11%
Core Operating Profit	2,997	3,678	-19%	-18%
Reported EPS	\$1.28	\$2.08	-38%	-39%
Core EPS	\$1.81	\$2.23	-19%	-19%



AstraZeneca PLC

2012 Annual General Meeting

Resolutions

1. To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2011
2. To confirm dividends
3. To re-appoint KPMG Audit Plc, London as Auditor
4. To authorise the Directors to agree the remuneration of the Auditor
5. To elect or re-elect the following as Directors:
 - a) Louis Schweitzer
 - b) David Brennan
 - c) Simon Lowth
 - d) Geneviève Berger
 - e) Bruce Burlington
 - f) Graham Chipchase
 - g) Jean-Philippe Courtois
 - h) Leif Johansson
 - i) Rudy Markham
 - j) Nancy Rothwell
 - k) Shriti Vadera
 - l) John Varley
 - m) Marcus Wallenberg
6. To approve the Directors' Remuneration Report for the year ended 31 December 2011
7. To authorise limited EU political donations
8. To authorise the Directors to allot shares
9. To approve the New SAYE Scheme
10. To authorise the Directors to disapply pre-emption rights
11. To authorise the Company to purchase its own shares
12. To reduce the notice period for general meetings

AstraZeneca PLC

2012 Annual General Meeting

Resolutions

1. To receive the Company's Accounts and the Reports of the Directors and Auditor for the year ended 31 December 2011
2. To confirm dividends
3. To re-appoint KPMG Audit Plc, London as Auditor
4. To authorise the Directors to agree the remuneration of the Auditor
5. To elect or re-elect the following as Directors:
 - a) Louis Schweitzer
 - b) David Brennan
 - c) Simon Lowth
 - d) Geneviève Berger
 - e) Bruce Burlington
 - f) Graham Chipchase
 - g) Jean-Philippe Courtois
 - h) Leif Johansson
 - i) Rudy Markham
 - j) Nancy Rothwell
 - k) Shriti Vadera
 - l) John Varley
 - m) Marcus Wallenberg
6. To approve the Directors' Remuneration Report for the year ended 31 December 2011
7. To authorise limited EU political donations
8. To authorise the Directors to allot shares
9. To approve the New SAYE Scheme
10. To authorise the Directors to disapply pre-emption rights
11. To authorise the Company to purchase its own shares
12. To reduce the notice period for general meetings

AstraZeneca PLC

2012 Annual General Meeting

- **Please place your completed Polling Card in one of the boxes as you leave the meeting room**
- **We expect to announce the results of the poll later today**
- **The results of the poll will also be published in the Investors section of our website, astrazeneca.com**

AstraZeneca PLC

2012 Annual General Meeting

Thank you for attending and have a safe journey home